These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32659267)

  • 1. Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response.
    Hannan MA; Rahman MA; Rahman MS; Sohag AAM; Dash R; Hossain KS; Farjana M; Uddin MJ
    Immunol Lett; 2020 Oct; 226():38-45. PubMed ID: 32659267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cell Dysfunction and Its Role in COVID-19.
    van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection.
    Huizinga GP; Singer BH; Singer K
    Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32880654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immune Response and Immunopathology of COVID-19.
    Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
    Front Immunol; 2020; 11():2037. PubMed ID: 32983152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covid-19: Perspectives on Innate Immune Evasion.
    Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
    Front Immunol; 2020; 11():580641. PubMed ID: 33101306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses.
    Gadi N; Wu SC; Spihlman AP; Moulton VR
    Front Immunol; 2020; 11():2147. PubMed ID: 32983176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research.
    Ray S; Srivastava S
    OMICS; 2020 Aug; 24(8):457-459. PubMed ID: 32427517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
    Bouayad A
    Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.
    Wong NA; Saier MH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link?
    Rebello CJ; Kirwan JP; Greenway FL
    Int J Obes (Lond); 2020 Sep; 44(9):1810-1817. PubMed ID: 32647360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
    Prompetchara E; Ketloy C; Palaga T
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):1-9. PubMed ID: 32105090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?
    Mondal R; Lahiri D; Deb S; Bandyopadhyay D; Shome G; Sarkar S; Paria SR; Thakurta TG; Singla P; Biswas SC
    J Thromb Thrombolysis; 2020 Oct; 50(3):567-579. PubMed ID: 32627126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.